Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRB NYSEMKT:PHGE OTCMKTS:PURE OTCMKTS:SZLSF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$4.99+0.4%$7.97$4.36▼$94.50$9.03M0.51145,702 shs54,090 shsPHGEBiomX$0.40-46.1%$0.47$0.34▼$3.48$10.03M1.41340,405 shs53,300 shsPUREPURE Bioscience$0.08+28.3%$0.09$0.05▼$0.21$9.48M0.3158,817 shs24,805 shsSZLSFStagezero Life Sciences$0.02$0.01$0.00▼$1.00$2.82M-0.153,035 shsN/AInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-1.39%+0.81%-52.86%-44.59%-93.68%PHGEBiomX-2.26%-5.12%+0.78%-27.29%-88.56%PUREPURE Bioscience-2.22%-20.48%-22.54%+6.45%-11.29%SZLSFStagezero Life Sciences0.00%0.00%-20.56%+20.00%+52.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences2.2612 of 5 stars3.22.00.00.01.61.71.3PHGEBiomX2.2631 of 5 stars3.50.00.00.01.70.81.3PUREPURE Bioscience0.2396 of 5 stars0.03.00.00.00.61.70.0SZLSFStagezero Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.33Hold$375.007,415.03% UpsidePHGEBiomX 3.00Buy$21.005,176.38% UpsidePUREPURE Bioscience 0.00N/AN/AN/ASZLSFStagezero Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SZLSF, PHGE, PURE, and CLRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025PHGEBiomXHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/APHGEBiomXN/AN/AN/AN/A$0.70 per shareN/APUREPURE Bioscience$1.96M4.84N/AN/A($0.03) per share-2.82SZLSFStagezero Life Sciences$3.80M0.74N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/13/2025 (Estimated)PHGEBiomX-$28.32M-$0.85N/AN/AN/AN/A-127.82%-56.50%N/APUREPURE Bioscience-$3.35M-$0.04N/A∞N/A-147.72%N/A-334.78%N/ASZLSFStagezero Life Sciences-$11.41MN/A0.00∞N/AN/AN/AN/AN/ALatest SZLSF, PHGE, PURE, and CLRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CLRBCellectar Biosciences-$3.70N/AN/AN/AN/AN/A6/16/2025Q3 2025PUREPURE BioscienceN/A-$0.01N/A-$0.01N/A$0.49 million5/13/2025Q1 2025CLRBCellectar Biosciences-$5.10-$3.90+$1.20-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/APUREPURE BioscienceN/AN/AN/AN/AN/ASZLSFStagezero Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A2.472.47PHGEBiomX0.512.842.84PUREPURE BioscienceN/A1.080.94SZLSFStagezero Life SciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%PHGEBiomX40.57%PUREPURE BioscienceN/ASZLSFStagezero Life SciencesN/AInsider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences5.04%PHGEBiomX1.17%PUREPURE Bioscience43.54%SZLSFStagezero Life Sciences2.54%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences101.81 million1.72 millionOptionablePHGEBiomX12026.18 million44.04 millionNot OptionablePUREPURE Bioscience10111.89 million63.17 millionNot OptionableSZLSFStagezero Life Sciences80123.53 million120.40 millionNot OptionableSZLSF, PHGE, PURE, and CLRB HeadlinesRecent News About These CompaniesStageZero Life Sciences and ElevationMD Introduce Aristotle and AVRT for the Early Detection of CancerMay 13, 2025 | thenewswire.comTStageZero Life Sciences Ltd. (SZLSF)July 27, 2024 | finance.yahoo.comStageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade OrderJuly 9, 2024 | accesswire.comAStageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials under the Failure to File Cease Trade OrderJuly 3, 2024 | accesswire.comAStageZero Life Sciences Ltd: StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational UpdateMay 17, 2024 | finanznachrichten.deStageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational UpdateMay 17, 2024 | accesswire.comAStageZero Life Sciences Ltd: StageZero Life Sciences Provides an Update on Application for Management Cease Trade OrderApril 5, 2024 | finanznachrichten.deStageZero Life Sciences Provides an Update on Application for Management Cease Trade OrderApril 5, 2024 | accesswire.comAStageZero Life Sciences Announces Delay to Fourth Quarter and Year End 2023 Financial ResultsApril 2, 2024 | accesswire.comAStagezero Life Sciences GAAP EPS of -$0.01, revenue of $0.75MNovember 15, 2023 | seekingalpha.comStageZero Life Sciences, Ltd Announces Results of Resolutions at Annual and Special MeetingJune 7, 2023 | finance.yahoo.comDually-Listed Healthcare Stock Rallies On Q1 ResultsMay 17, 2023 | theglobeandmail.comStageZero to Issue Q1 2023 Financial Results After Market Closes May 15, 2023May 15, 2023 | finance.yahoo.comStagezero Life Sciences GAAP EPS of -$0.09, revenue of $0.7MApril 3, 2023 | msn.comStageZero to Issue Q4 2022 Financial Results on Friday March 31March 30, 2023 | finance.yahoo.comStageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Thursday March 30March 29, 2023 | finance.yahoo.comResults from METRICs Study Informs Expansion of StageZero's New Care Oncology ProtocolFebruary 15, 2023 | finance.yahoo.comStageZero Life Sciences Ltd: StageZero Life Sciences Announces Extension of Warrants Expiring in January 2023January 12, 2023 | finanznachrichten.deStageZero Life Sciences Announces Extension of Warrants Expiring in January 2023January 12, 2023 | finance.yahoo.comStageZero Life Sciences Ltd. (SZLSF) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSZLSF, PHGE, PURE, and CLRB Company DescriptionsCellectar Biosciences NASDAQ:CLRB$4.99 +0.02 (+0.40%) Closing price 04:00 PM EasternExtended Trading$5.04 +0.05 (+0.98%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.BiomX NYSEMKT:PHGE$0.40 -0.34 (-46.14%) Closing price 03:58 PM EasternExtended Trading$0.40 0.00 (-0.25%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.PURE Bioscience OTCMKTS:PURE$0.08 +0.02 (+28.33%) As of 03:31 PM EasternPURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.Stagezero Life Sciences OTCMKTS:SZLSF$0.02 0.00 (0.00%) As of 07/15/2025StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
